Tesla Expands Supercharger Network Via Partnership With Major Gas Station Operator

Tesla Inc (NASDAQ: TSLA) is expanding its Supercharger network reach through a new deal with EG Group, a leading gas station and convenience store operator.

Tesla Inc (NASDAQ:TSLA) is expanding its Supercharger network reach through a new deal with EG Group, a leading gas station and convenience store operator. This agreement allows EG Group to purchase Tesla’s Supercharger hardware, which will be deployed under the EG brand. This development marks Tesla’s second major deal in recent weeks, indicating a significant shift in the company’s approach to its charging infrastructure, as shared by Electrek.

$100 million BP Deal

Previously, Tesla had struck a deal with BP, selling $100 million worth of Supercharger hardware for deployment at BP gas stations across the U.S. under the BP brand. This move was one of the first instances of Tesla selling its Supercharger technology to third-party entities on such a large scale. Rebecca Tinucci, Tesla’s head of charging infrastructure, mentioned that this venture represents a new business direction for Tesla. This strategy is quickly gaining momentum, as evidenced by the latest deal with EG Group.

EG Deal

EG Group announced its agreement with Tesla, stating that it would integrate Tesla’s ultra-fast charging units into its ‘evpoint’ business, focusing on the UK and European markets. The chargers, branded as “evpoint,” will utilize Tesla’s technology but will operate on an open network, allowing all drivers, regardless of vehicle brand, to access these chargers. They will also support the Plug and Charge protocol, simplifying and automating the payment process. The first installations of these new units are expected to roll out before the year’s end.

Photo courtesy of Tesla

Total
0
Shares
Related Posts
Read More

Opthea’s Phase 2B Results Of OPT-302, Anti-VEGF-C/-D “Trap” Agent Administered In Combination With Lucentis (Ranibizumab) For Wet Age-Related Macular Degeneration Have Been Published In Ophthalmology, Journal Of The American Academy Ophthalmology

The prospective, randomized, controlled Phase 2b trial of 366 treatment-naïve patients with wet AMD, demonstrated that monthly intravitreal administration of 2.0 mg OPT-302 with ranibizumab standard of care, met the

OPT